drugset / Trial / NCT04732598
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Phase 3
Completed
281 enrolled
Japanese Foundation for Cancer Research
Chugai Pharmaceutical · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive HER2 negative metastatic breast cancer.
Timeline
- Start
- 2021-01-21
- Primary completion
- 2025-09-12
- Completion
- 2026-03-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 unknown | — |
| Comparator | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Comparator | Paclitaxel | Small molecule | 90 mg/m2 | — |